<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03991494</url>
  </required_header>
  <id_info>
    <org_study_id>BGB-290-106</org_study_id>
    <secondary_id>2018-001156-36</secondary_id>
    <nct_id>NCT03991494</nct_id>
  </id_info>
  <brief_title>Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-Pamiparib in Participants With Advanced Cancer</brief_title>
  <official_title>A Phase 1 Study to Investigate the Absorption, Metabolism, and Excretion of [14C]Pamiparib Following Single Oral Dose Administration in Patients With Advanced and/or Metastatic Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BeiGene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BeiGene</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label study, in participants with advanced and/or metastatic solid tumors,
      which consists of 2 parts: a research phase (inpatient) and a treatment phase. The research
      phase (Part 1) of the study will assess the disposition of a single oral dose of
      [14C]-pamiparib. In the treatment phase (Part 2) participants will be allowed to have
      continued access to pamiparib.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 18, 2019</start_date>
  <completion_date type="Actual">July 1, 2020</completion_date>
  <primary_completion_date type="Actual">October 22, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma pharmacokinetics of total radioactivity and pamiparib following a single oral dose of [14C]-pamiparib</measure>
    <time_frame>Up to 7 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Whole blood concentrations of total radioactivity</measure>
    <time_frame>Up to 7 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentrations of total radioactivity</measure>
    <time_frame>Up to 7 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Urinary recovery of total radioactivity</measure>
    <time_frame>Up to 7 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Fecal recovery of total radioactivity</measure>
    <time_frame>Up to 7 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Metabolites of [14C]-pamiparib in plasma</measure>
    <time_frame>Up to 7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolites of [14C]-pamiparib in urine</measure>
    <time_frame>Up to 7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolites of [14C]-pamiparib in feces</measure>
    <time_frame>Up to 7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations of pamiparib and/or its major metabolites</measure>
    <time_frame>Up to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine concentrations of pamiparib and/or its major metabolites</measure>
    <time_frame>Up to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence and severity of treatment-emergent adverse events (safety and tolerability)</measure>
    <time_frame>Up to 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Advanced Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Pamiparib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[14C]-pamiparib</intervention_name>
    <description>During the treatment phase, pamiparib 60 mg administered orally twice daily</description>
    <arm_group_label>Pamiparib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          1. Histologically and/or cytologically confirmed advanced or metastatic solid tumor that
             has progressed after treatment with approved therapies for which there are no standard
             therapies available

          2. A total body weight between 50 and 100 kg, inclusive at Screening

          3. Measurable disease by CT/MRI

          4. Eastern Cooperative Oncology Group (ECOG) performance status of ≤1

          5. Adequate organ function

        Key Exclusion Criteria:

          1. Clinically significant cardiovascular disease

          2. Have a previous complete gastric resection, chronic diarrhea, active inflammatory
             gastrointestinal disease, or any other disease causing malabsorption syndrome.

          3. Poor peripheral venous access

          4. Major surgical procedure, open biopsy, or significant traumatic injury ≤ 2 weeks prior
             to Day 1, or anticipation of need for major surgical procedure during the course of
             the study

          5. Use or have anticipated need for food or drugs known to be strong or moderate CYP3A
             inhibitors or strong CYP3A inducers

        NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Palmer, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royal Liverpool University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Clatterbridge Cancer Centre NHS Foundation Trust</name>
      <address>
        <city>Bebington</city>
        <state>Wirral</state>
        <zip>CH63 4JY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Liverpool University Hospital Clinical Research Unit</name>
      <address>
        <city>Liverpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 14, 2019</study_first_submitted>
  <study_first_submitted_qc>June 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 19, 2019</study_first_posted>
  <last_update_submitted>July 14, 2020</last_update_submitted>
  <last_update_submitted_qc>July 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

